nodes	percent_of_prediction	percent_of_DWPC	metapath
Nabumetone—osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.347	1	CpDpCtD
Nabumetone—MPO—chronic obstructive pulmonary disease	0.28	0.634	CbGaD
Nabumetone—CYP1A2—chronic obstructive pulmonary disease	0.162	0.366	CbGaD
Nabumetone—PTGS1—Montelukast—chronic obstructive pulmonary disease	0.0616	0.666	CbGbCtD
Nabumetone—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0309	0.334	CbGbCtD
Nabumetone—CYP1A2—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.00131	0.0444	CbGpPWpGaD
Nabumetone—MPO—C-MYB transcription factor network—ELANE—chronic obstructive pulmonary disease	0.00129	0.0436	CbGpPWpGaD
Nabumetone—PTGS1—Prostaglandin Synthesis and Regulation—SCGB1A1—chronic obstructive pulmonary disease	0.0012	0.0407	CbGpPWpGaD
Nabumetone—MPO—Vitamin B12 Metabolism—SOD3—chronic obstructive pulmonary disease	0.0011	0.0373	CbGpPWpGaD
Nabumetone—PTGS2—leg—chronic obstructive pulmonary disease	0.00108	0.2	CbGeAlD
Nabumetone—PTGS2—Prostaglandin Synthesis and Regulation—SCGB1A1—chronic obstructive pulmonary disease	0.000954	0.0323	CbGpPWpGaD
Nabumetone—MPO—Folate Metabolism—SOD3—chronic obstructive pulmonary disease	0.000898	0.0304	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—STAT4—chronic obstructive pulmonary disease	0.000895	0.0303	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—IL17A—chronic obstructive pulmonary disease	0.000881	0.0298	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—SOD3—chronic obstructive pulmonary disease	0.000713	0.0241	CbGpPWpGaD
Nabumetone—MPO—respiratory system—chronic obstructive pulmonary disease	0.000593	0.11	CbGeAlD
Nabumetone—Melatonin—MPO—chronic obstructive pulmonary disease	0.000577	0.237	CrCbGaD
Nabumetone—Agomelatine—CYP1A2—chronic obstructive pulmonary disease	0.00057	0.234	CrCbGaD
Nabumetone—MPO—connective tissue—chronic obstructive pulmonary disease	0.000522	0.0965	CbGeAlD
Nabumetone—MPO—IL23-mediated signaling events—NOS2—chronic obstructive pulmonary disease	0.000459	0.0155	CbGpPWpGaD
Nabumetone—PTGS1—Overview of nanoparticle effects—HMOX1—chronic obstructive pulmonary disease	0.000448	0.0152	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—ELANE—chronic obstructive pulmonary disease	0.000419	0.0142	CbGpPWpGaD
Nabumetone—CYP1A2—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.000417	0.0141	CbGpPWpGaD
Nabumetone—MPO—Vitamin B12 Metabolism—CRP—chronic obstructive pulmonary disease	0.00039	0.0132	CbGpPWpGaD
Nabumetone—Naproxen—CYP1A2—chronic obstructive pulmonary disease	0.000388	0.159	CrCbGaD
Nabumetone—PTGS2—Overview of nanoparticle effects—HMOX1—chronic obstructive pulmonary disease	0.000356	0.012	CbGpPWpGaD
Nabumetone—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.000355	0.012	CbGpPWpGaD
Nabumetone—PTGS1—Overview of nanoparticle effects—CRP—chronic obstructive pulmonary disease	0.000351	0.0119	CbGpPWpGaD
Nabumetone—Melatonin—CYP1A1—chronic obstructive pulmonary disease	0.000346	0.142	CrCbGaD
Nabumetone—Melatonin—CYP1A2—chronic obstructive pulmonary disease	0.000334	0.137	CrCbGaD
Nabumetone—CYP1A2—respiratory system—chronic obstructive pulmonary disease	0.000325	0.06	CbGeAlD
Nabumetone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—MMP1—chronic obstructive pulmonary disease	0.000324	0.0109	CbGpPWpGaD
Nabumetone—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.000324	0.0109	CbGpPWpGaD
Nabumetone—MPO—Folate Metabolism—CRP—chronic obstructive pulmonary disease	0.000317	0.0107	CbGpPWpGaD
Nabumetone—MPO—lung—chronic obstructive pulmonary disease	0.000315	0.0582	CbGeAlD
Nabumetone—MPO—IL23-mediated signaling events—IL1B—chronic obstructive pulmonary disease	0.000314	0.0106	CbGpPWpGaD
Nabumetone—MPO—C-MYB transcription factor network—GSTM1—chronic obstructive pulmonary disease	0.000311	0.0105	CbGpPWpGaD
Nabumetone—MPO—Vitamin B12 Metabolism—SERPINE1—chronic obstructive pulmonary disease	0.000299	0.0101	CbGpPWpGaD
Nabumetone—MPO—Vitamin B12 Metabolism—ALB—chronic obstructive pulmonary disease	0.000299	0.0101	CbGpPWpGaD
Nabumetone—PTGS1—Prostaglandin Synthesis and Regulation—EDN1—chronic obstructive pulmonary disease	0.000293	0.00992	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—SOD3—chronic obstructive pulmonary disease	0.000292	0.00988	CbGpPWpGaD
Nabumetone—PTGS1—respiratory system—chronic obstructive pulmonary disease	0.000281	0.052	CbGeAlD
Nabumetone—PTGS2—Overview of nanoparticle effects—CRP—chronic obstructive pulmonary disease	0.000279	0.00944	CbGpPWpGaD
Nabumetone—PTGS2—respiratory system—chronic obstructive pulmonary disease	0.000269	0.0497	CbGeAlD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—GCLC—chronic obstructive pulmonary disease	0.000254	0.00858	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—CRP—chronic obstructive pulmonary disease	0.000252	0.00852	CbGpPWpGaD
Nabumetone—PTGS1—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000251	0.00851	CbGpPWpGaD
Nabumetone—PTGS1—connective tissue—chronic obstructive pulmonary disease	0.000248	0.0458	CbGeAlD
Nabumetone—MPO—Folate Metabolism—SERPINE1—chronic obstructive pulmonary disease	0.000243	0.00824	CbGpPWpGaD
Nabumetone—MPO—Vitamin B12 Metabolism—IL1B—chronic obstructive pulmonary disease	0.000243	0.00822	CbGpPWpGaD
Nabumetone—MPO—Folate Metabolism—ALB—chronic obstructive pulmonary disease	0.000243	0.00822	CbGpPWpGaD
Nabumetone—CYP1A2—Estrogen Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	0.000241	0.00816	CbGpPWpGaD
Nabumetone—PTGS2—connective tissue—chronic obstructive pulmonary disease	0.000237	0.0438	CbGeAlD
Nabumetone—PTGS2—Prostaglandin Synthesis and Regulation—EDN1—chronic obstructive pulmonary disease	0.000233	0.00788	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—SOD3—chronic obstructive pulmonary disease	0.000232	0.00784	CbGpPWpGaD
Nabumetone—PTGS1—Overview of nanoparticle effects—CXCL8—chronic obstructive pulmonary disease	0.000228	0.00773	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—TNF—chronic obstructive pulmonary disease	0.000228	0.00771	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—MMP12—chronic obstructive pulmonary disease	0.000227	0.00769	CbGpPWpGaD
Nabumetone—PTGS1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000226	0.0419	CbGeAlD
Nabumetone—Naproxen—ALB—chronic obstructive pulmonary disease	0.000224	0.0918	CrCbGaD
Nabumetone—PTGS2—bronchus—chronic obstructive pulmonary disease	0.000221	0.0409	CbGeAlD
Nabumetone—PTGS2—smooth muscle tissue—chronic obstructive pulmonary disease	0.000216	0.04	CbGeAlD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—CYP1A2—chronic obstructive pulmonary disease	0.000213	0.00722	CbGpPWpGaD
Nabumetone—PTGS1—trachea—chronic obstructive pulmonary disease	0.000208	0.0384	CbGeAlD
Nabumetone—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000204	0.00691	CbGpPWpGaD
Nabumetone—PTGS2—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.0002	0.00675	CbGpPWpGaD
Nabumetone—PTGS2—trachea—chronic obstructive pulmonary disease	0.000199	0.0367	CbGeAlD
Nabumetone—MPO—Folate Metabolism—IL1B—chronic obstructive pulmonary disease	0.000198	0.00669	CbGpPWpGaD
Nabumetone—Tension—Salbutamol—chronic obstructive pulmonary disease	0.000198	0.00241	CcSEcCtD
Nabumetone—Vasculitis—Prednisone—chronic obstructive pulmonary disease	0.000197	0.0024	CcSEcCtD
Nabumetone—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000196	0.00239	CcSEcCtD
Nabumetone—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000196	0.00239	CcSEcCtD
Nabumetone—CYP1A2—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000196	0.00663	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—MPO—chronic obstructive pulmonary disease	0.000196	0.00663	CbGpPWpGaD
Nabumetone—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000196	0.00239	CcSEcCtD
Nabumetone—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.000196	0.00239	CcSEcCtD
Nabumetone—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000195	0.00238	CcSEcCtD
Nabumetone—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000195	0.00238	CcSEcCtD
Nabumetone—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000195	0.00238	CcSEcCtD
Nabumetone—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000194	0.00237	CcSEcCtD
Nabumetone—MPO—Selenium Micronutrient Network—SERPINE1—chronic obstructive pulmonary disease	0.000193	0.00654	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—ALB—chronic obstructive pulmonary disease	0.000193	0.00653	CbGpPWpGaD
Nabumetone—Malaise—Formoterol—chronic obstructive pulmonary disease	0.000192	0.00235	CcSEcCtD
Nabumetone—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.000192	0.00235	CcSEcCtD
Nabumetone—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000192	0.00235	CcSEcCtD
Nabumetone—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000191	0.00233	CcSEcCtD
Nabumetone—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.00019	0.00232	CcSEcCtD
Nabumetone—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000189	0.0023	CcSEcCtD
Nabumetone—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000189	0.0023	CcSEcCtD
Nabumetone—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000189	0.0023	CcSEcCtD
Nabumetone—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000187	0.00228	CcSEcCtD
Nabumetone—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.000187	0.00228	CcSEcCtD
Nabumetone—Cough—Formoterol—chronic obstructive pulmonary disease	0.000186	0.00227	CcSEcCtD
Nabumetone—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000186	0.00227	CcSEcCtD
Nabumetone—CYP1A2—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000186	0.00629	CbGpPWpGaD
Nabumetone—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000185	0.00226	CcSEcCtD
Nabumetone—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000185	0.00226	CcSEcCtD
Nabumetone—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000185	0.00225	CcSEcCtD
Nabumetone—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000184	0.00225	CcSEcCtD
Nabumetone—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000184	0.00225	CcSEcCtD
Nabumetone—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000184	0.00225	CcSEcCtD
Nabumetone—MPO—IL23-mediated signaling events—IL6—chronic obstructive pulmonary disease	0.000184	0.00622	CbGpPWpGaD
Nabumetone—PTGS1—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000183	0.00618	CbGpPWpGaD
Nabumetone—Cough—Montelukast—chronic obstructive pulmonary disease	0.000182	0.00223	CcSEcCtD
Nabumetone—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000182	0.00222	CcSEcCtD
Nabumetone—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000182	0.00222	CcSEcCtD
Nabumetone—PTGS2—Overview of nanoparticle effects—CXCL8—chronic obstructive pulmonary disease	0.000181	0.00614	CbGpPWpGaD
Nabumetone—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000181	0.00221	CcSEcCtD
Nabumetone—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000181	0.00221	CcSEcCtD
Nabumetone—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.000181	0.00221	CcSEcCtD
Nabumetone—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000181	0.00221	CcSEcCtD
Nabumetone—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000181	0.00221	CcSEcCtD
Nabumetone—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000181	0.00221	CcSEcCtD
Nabumetone—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00018	0.00219	CcSEcCtD
Nabumetone—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.00018	0.00219	CcSEcCtD
Nabumetone—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000178	0.00217	CcSEcCtD
Nabumetone—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000178	0.00217	CcSEcCtD
Nabumetone—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000178	0.00217	CcSEcCtD
Nabumetone—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000177	0.00217	CcSEcCtD
Nabumetone—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000177	0.00216	CcSEcCtD
Nabumetone—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000176	0.00215	CcSEcCtD
Nabumetone—MPO—Vitamin B12 Metabolism—TNF—chronic obstructive pulmonary disease	0.000176	0.00597	CbGpPWpGaD
Nabumetone—PTGS1—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000176	0.00596	CbGpPWpGaD
Nabumetone—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000176	0.00215	CcSEcCtD
Nabumetone—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000174	0.00213	CcSEcCtD
Nabumetone—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000174	0.00213	CcSEcCtD
Nabumetone—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000174	0.00213	CcSEcCtD
Nabumetone—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000174	0.00213	CcSEcCtD
Nabumetone—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000174	0.00212	CcSEcCtD
Nabumetone—CYP1A2—lung—chronic obstructive pulmonary disease	0.000172	0.0319	CbGeAlD
Nabumetone—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000171	0.00209	CcSEcCtD
Nabumetone—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000171	0.00209	CcSEcCtD
Nabumetone—CYP1A2—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000171	0.00578	CbGpPWpGaD
Nabumetone—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000171	0.00208	CcSEcCtD
Nabumetone—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000171	0.00208	CcSEcCtD
Nabumetone—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000171	0.00208	CcSEcCtD
Nabumetone—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000169	0.00207	CcSEcCtD
Nabumetone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—chronic obstructive pulmonary disease	0.000169	0.00572	CbGpPWpGaD
Nabumetone—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000169	0.00206	CcSEcCtD
Nabumetone—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000168	0.00205	CcSEcCtD
Nabumetone—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000167	0.00204	CcSEcCtD
Nabumetone—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000164	0.00201	CcSEcCtD
Nabumetone—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000164	0.00201	CcSEcCtD
Nabumetone—CYP1A2—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000164	0.00556	CbGpPWpGaD
Nabumetone—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000163	0.00199	CcSEcCtD
Nabumetone—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000162	0.00198	CcSEcCtD
Nabumetone—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000162	0.00198	CcSEcCtD
Nabumetone—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	0.000162	0.00197	CcSEcCtD
Nabumetone—PTGS2—C-MYB transcription factor network—MPO—chronic obstructive pulmonary disease	0.000161	0.00546	CbGpPWpGaD
Nabumetone—Thrombophlebitis—Prednisone—chronic obstructive pulmonary disease	0.000161	0.00197	CcSEcCtD
Nabumetone—PTGS1—Overview of nanoparticle effects—TNF—chronic obstructive pulmonary disease	0.000159	0.00538	CbGpPWpGaD
Nabumetone—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000159	0.00194	CcSEcCtD
Nabumetone—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000159	0.00194	CcSEcCtD
Nabumetone—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000158	0.00192	CcSEcCtD
Nabumetone—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000158	0.00192	CcSEcCtD
Nabumetone—MPO—Selenium Micronutrient Network—IL1B—chronic obstructive pulmonary disease	0.000157	0.00532	CbGpPWpGaD
Nabumetone—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000157	0.00191	CcSEcCtD
Nabumetone—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000157	0.00191	CcSEcCtD
Nabumetone—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—chronic obstructive pulmonary disease	0.000156	0.00528	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—MPO—chronic obstructive pulmonary disease	0.000156	0.00526	CbGpPWpGaD
Nabumetone—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000155	0.0019	CcSEcCtD
Nabumetone—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000155	0.0019	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—CYP1A1—chronic obstructive pulmonary disease	0.000155	0.00524	CbGpPWpGaD
Nabumetone—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000155	0.00189	CcSEcCtD
Nabumetone—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000155	0.00189	CcSEcCtD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—RAPGEF3—chronic obstructive pulmonary disease	0.000155	0.00523	CbGpPWpGaD
Nabumetone—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000154	0.00188	CcSEcCtD
Nabumetone—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000153	0.00187	CcSEcCtD
Nabumetone—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000153	0.00187	CcSEcCtD
Nabumetone—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000153	0.00187	CcSEcCtD
Nabumetone—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000153	0.00186	CcSEcCtD
Nabumetone—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000152	0.00185	CcSEcCtD
Nabumetone—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000151	0.00185	CcSEcCtD
Nabumetone—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000151	0.00184	CcSEcCtD
Nabumetone—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.00015	0.00183	CcSEcCtD
Nabumetone—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.00015	0.00183	CcSEcCtD
Nabumetone—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.00015	0.00183	CcSEcCtD
Nabumetone—PTGS1—lung—chronic obstructive pulmonary disease	0.000149	0.0276	CbGeAlD
Nabumetone—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000149	0.00182	CcSEcCtD
Nabumetone—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000149	0.00182	CcSEcCtD
Nabumetone—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000149	0.00182	CcSEcCtD
Nabumetone—Increased appetite—Prednisone—chronic obstructive pulmonary disease	0.000148	0.00181	CcSEcCtD
Nabumetone—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000148	0.0018	CcSEcCtD
Nabumetone—PTGS2—S1P1 pathway—VEGFA—chronic obstructive pulmonary disease	0.000147	0.00498	CbGpPWpGaD
Nabumetone—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000147	0.0018	CcSEcCtD
Nabumetone—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000147	0.00179	CcSEcCtD
Nabumetone—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000146	0.00178	CcSEcCtD
Nabumetone—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000146	0.00178	CcSEcCtD
Nabumetone—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000146	0.00178	CcSEcCtD
Nabumetone—PTGS2—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000145	0.00491	CbGpPWpGaD
Nabumetone—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000145	0.00177	CcSEcCtD
Nabumetone—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000145	0.00177	CcSEcCtD
Nabumetone—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000144	0.00176	CcSEcCtD
Nabumetone—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000144	0.00176	CcSEcCtD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—GCLC—chronic obstructive pulmonary disease	0.000144	0.00486	CbGpPWpGaD
Nabumetone—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000144	0.00175	CcSEcCtD
Nabumetone—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000144	0.00175	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—TNF—chronic obstructive pulmonary disease	0.000144	0.00485	CbGpPWpGaD
Nabumetone—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000143	0.00175	CcSEcCtD
Nabumetone—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000143	0.00175	CcSEcCtD
Nabumetone—PTGS2—lung—chronic obstructive pulmonary disease	0.000143	0.0264	CbGeAlD
Nabumetone—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000143	0.00174	CcSEcCtD
Nabumetone—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000142	0.00174	CcSEcCtD
Nabumetone—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000142	0.00174	CcSEcCtD
Nabumetone—MPO—Vitamin B12 Metabolism—IL6—chronic obstructive pulmonary disease	0.000142	0.00482	CbGpPWpGaD
Nabumetone—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000142	0.00173	CcSEcCtD
Nabumetone—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000141	0.00172	CcSEcCtD
Nabumetone—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.00014	0.0017	CcSEcCtD
Nabumetone—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000139	0.0017	CcSEcCtD
Nabumetone—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000138	0.00169	CcSEcCtD
Nabumetone—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000138	0.00169	CcSEcCtD
Nabumetone—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000138	0.00168	CcSEcCtD
Nabumetone—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000138	0.00168	CcSEcCtD
Nabumetone—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000138	0.00168	CcSEcCtD
Nabumetone—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000138	0.00168	CcSEcCtD
Nabumetone—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000137	0.00168	CcSEcCtD
Nabumetone—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000136	0.00166	CcSEcCtD
Nabumetone—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000136	0.00166	CcSEcCtD
Nabumetone—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000136	0.00166	CcSEcCtD
Nabumetone—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000136	0.00165	CcSEcCtD
Nabumetone—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000136	0.00165	CcSEcCtD
Nabumetone—CYP1A2—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000135	0.00458	CbGpPWpGaD
Nabumetone—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000135	0.00165	CcSEcCtD
Nabumetone—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000135	0.00165	CcSEcCtD
Nabumetone—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000135	0.00165	CcSEcCtD
Nabumetone—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000134	0.00164	CcSEcCtD
Nabumetone—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000133	0.00163	CcSEcCtD
Nabumetone—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000133	0.00162	CcSEcCtD
Nabumetone—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000131	0.0016	CcSEcCtD
Nabumetone—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.00013	0.00159	CcSEcCtD
Nabumetone—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.00013	0.00159	CcSEcCtD
Nabumetone—PTGS1—Overview of nanoparticle effects—IL6—chronic obstructive pulmonary disease	0.000128	0.00434	CbGpPWpGaD
Nabumetone—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000128	0.00157	CcSEcCtD
Nabumetone—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000128	0.00157	CcSEcCtD
Nabumetone—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000128	0.00157	CcSEcCtD
Nabumetone—PTGS1—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000128	0.00433	CbGpPWpGaD
Nabumetone—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000128	0.00156	CcSEcCtD
Nabumetone—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000127	0.00155	CcSEcCtD
Nabumetone—CYP1A2—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000127	0.00429	CbGpPWpGaD
Nabumetone—MPO—Folate Metabolism—TP53—chronic obstructive pulmonary disease	0.000127	0.00428	CbGpPWpGaD
Nabumetone—PTGS2—Overview of nanoparticle effects—TNF—chronic obstructive pulmonary disease	0.000126	0.00427	CbGpPWpGaD
Nabumetone—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000126	0.00153	CcSEcCtD
Nabumetone—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000125	0.00153	CcSEcCtD
Nabumetone—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000125	0.00153	CcSEcCtD
Nabumetone—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000123	0.0015	CcSEcCtD
Nabumetone—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000123	0.0015	CcSEcCtD
Nabumetone—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000122	0.00149	CcSEcCtD
Nabumetone—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000121	0.00148	CcSEcCtD
Nabumetone—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000121	0.00147	CcSEcCtD
Nabumetone—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000119	0.00145	CcSEcCtD
Nabumetone—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000119	0.00145	CcSEcCtD
Nabumetone—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000119	0.00145	CcSEcCtD
Nabumetone—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000118	0.00144	CcSEcCtD
Nabumetone—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000118	0.00144	CcSEcCtD
Nabumetone—Sweating increased—Prednisone—chronic obstructive pulmonary disease	0.000117	0.00143	CcSEcCtD
Nabumetone—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000117	0.00143	CcSEcCtD
Nabumetone—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000116	0.00142	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—IL6—chronic obstructive pulmonary disease	0.000116	0.00392	CbGpPWpGaD
Nabumetone—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000115	0.00141	CcSEcCtD
Nabumetone—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000115	0.00141	CcSEcCtD
Nabumetone—MPO—Selenium Micronutrient Network—TNF—chronic obstructive pulmonary disease	0.000114	0.00386	CbGpPWpGaD
Nabumetone—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000113	0.00138	CcSEcCtD
Nabumetone—PTGS1—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000113	0.00381	CbGpPWpGaD
Nabumetone—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000113	0.00137	CcSEcCtD
Nabumetone—PTGS1—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000111	0.00377	CbGpPWpGaD
Nabumetone—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000111	0.00136	CcSEcCtD
Nabumetone—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000111	0.00135	CcSEcCtD
Nabumetone—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000111	0.00135	CcSEcCtD
Nabumetone—Rash—Arformoterol—chronic obstructive pulmonary disease	0.00011	0.00134	CcSEcCtD
Nabumetone—Rash—Formoterol—chronic obstructive pulmonary disease	0.00011	0.00134	CcSEcCtD
Nabumetone—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.00011	0.00134	CcSEcCtD
Nabumetone—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.00011	0.00134	CcSEcCtD
Nabumetone—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.00011	0.00134	CcSEcCtD
Nabumetone—Headache—Formoterol—chronic obstructive pulmonary disease	0.000109	0.00133	CcSEcCtD
Nabumetone—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000109	0.00133	CcSEcCtD
Nabumetone—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000109	0.00133	CcSEcCtD
Nabumetone—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000109	0.00133	CcSEcCtD
Nabumetone—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000109	0.00133	CcSEcCtD
Nabumetone—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000108	0.00132	CcSEcCtD
Nabumetone—Rash—Montelukast—chronic obstructive pulmonary disease	0.000108	0.00131	CcSEcCtD
Nabumetone—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000107	0.00131	CcSEcCtD
Nabumetone—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000107	0.00131	CcSEcCtD
Nabumetone—Depression—Prednisone—chronic obstructive pulmonary disease	0.000107	0.00131	CcSEcCtD
Nabumetone—Headache—Montelukast—chronic obstructive pulmonary disease	0.000107	0.0013	CcSEcCtD
Nabumetone—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000106	0.00129	CcSEcCtD
Nabumetone—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000106	0.00129	CcSEcCtD
Nabumetone—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000105	0.00129	CcSEcCtD
Nabumetone—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000105	0.00128	CcSEcCtD
Nabumetone—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000104	0.00127	CcSEcCtD
Nabumetone—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000104	0.00127	CcSEcCtD
Nabumetone—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000104	0.00127	CcSEcCtD
Nabumetone—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000104	0.00127	CcSEcCtD
Nabumetone—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000104	0.00126	CcSEcCtD
Nabumetone—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000103	0.00126	CcSEcCtD
Nabumetone—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000103	0.00126	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—CRP—chronic obstructive pulmonary disease	0.000103	0.00349	CbGpPWpGaD
Nabumetone—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000103	0.00126	CcSEcCtD
Nabumetone—PTGS2—Overview of nanoparticle effects—IL6—chronic obstructive pulmonary disease	0.000102	0.00345	CbGpPWpGaD
Nabumetone—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000102	0.00124	CcSEcCtD
Nabumetone—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000101	0.00124	CcSEcCtD
Nabumetone—PTGS2—C-MYB transcription factor network—GSTM1—chronic obstructive pulmonary disease	0.000101	0.00342	CbGpPWpGaD
Nabumetone—CYP1A2—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	9.98e-05	0.00338	CbGpPWpGaD
Nabumetone—Hypertension—Prednisolone—chronic obstructive pulmonary disease	9.98e-05	0.00122	CcSEcCtD
Nabumetone—Nausea—Salbutamol—chronic obstructive pulmonary disease	9.77e-05	0.00119	CcSEcCtD
Nabumetone—Discomfort—Prednisolone—chronic obstructive pulmonary disease	9.72e-05	0.00119	CcSEcCtD
Nabumetone—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	9.7e-05	0.00118	CcSEcCtD
Nabumetone—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	9.65e-05	0.00118	CcSEcCtD
Nabumetone—Oedema—Prednisolone—chronic obstructive pulmonary disease	9.43e-05	0.00115	CcSEcCtD
Nabumetone—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	9.43e-05	0.00115	CcSEcCtD
Nabumetone—PTGS1—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	9.36e-05	0.00317	CbGpPWpGaD
Nabumetone—Shock—Prednisolone—chronic obstructive pulmonary disease	9.28e-05	0.00113	CcSEcCtD
Nabumetone—MPO—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	9.2e-05	0.00311	CbGpPWpGaD
Nabumetone—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	9.12e-05	0.00111	CcSEcCtD
Nabumetone—CYP1A2—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	8.77e-05	0.00297	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—chronic obstructive pulmonary disease	8.77e-05	0.00297	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	8.77e-05	0.00297	CbGpPWpGaD
Nabumetone—CYP1A2—Phase II conjugation—GSTT1—chronic obstructive pulmonary disease	8.65e-05	0.00292	CbGpPWpGaD
Nabumetone—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	8.62e-05	0.00105	CcSEcCtD
Nabumetone—CYP1A2—Phase II conjugation—GCLC—chronic obstructive pulmonary disease	8.55e-05	0.00289	CbGpPWpGaD
Nabumetone—Insomnia—Prednisolone—chronic obstructive pulmonary disease	8.53e-05	0.00104	CcSEcCtD
Nabumetone—Alopecia—Prednisone—chronic obstructive pulmonary disease	8.53e-05	0.00104	CcSEcCtD
Nabumetone—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	8.47e-05	0.00103	CcSEcCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—chronic obstructive pulmonary disease	8.36e-05	0.00283	CbGpPWpGaD
Nabumetone—CYP1A2—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	8.21e-05	0.00278	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—CRP—chronic obstructive pulmonary disease	8.18e-05	0.00277	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—SERPINE1—chronic obstructive pulmonary disease	7.91e-05	0.00268	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	7.91e-05	0.00268	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—ALB—chronic obstructive pulmonary disease	7.9e-05	0.00267	CbGpPWpGaD
Nabumetone—PTGS1—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	7.8e-05	0.00264	CbGpPWpGaD
Nabumetone—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	7.79e-05	0.000951	CcSEcCtD
Nabumetone—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	7.77e-05	0.000949	CcSEcCtD
Nabumetone—Anaemia—Prednisone—chronic obstructive pulmonary disease	7.76e-05	0.000948	CcSEcCtD
Nabumetone—Agitation—Prednisone—chronic obstructive pulmonary disease	7.72e-05	0.000942	CcSEcCtD
Nabumetone—Angioedema—Prednisone—chronic obstructive pulmonary disease	7.67e-05	0.000937	CcSEcCtD
Nabumetone—Malaise—Prednisone—chronic obstructive pulmonary disease	7.57e-05	0.000925	CcSEcCtD
Nabumetone—Vertigo—Prednisone—chronic obstructive pulmonary disease	7.55e-05	0.000921	CcSEcCtD
Nabumetone—Syncope—Prednisone—chronic obstructive pulmonary disease	7.53e-05	0.00092	CcSEcCtD
Nabumetone—Urticaria—Prednisolone—chronic obstructive pulmonary disease	7.49e-05	0.000915	CcSEcCtD
Nabumetone—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	7.38e-05	0.000901	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	7.26e-05	0.00246	CbGpPWpGaD
Nabumetone—Hypertension—Prednisone—chronic obstructive pulmonary disease	7.25e-05	0.000885	CcSEcCtD
Nabumetone—PTGS1—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	7.17e-05	0.00243	CbGpPWpGaD
Nabumetone—Anxiety—Prednisone—chronic obstructive pulmonary disease	7.13e-05	0.00087	CcSEcCtD
Nabumetone—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	7.09e-05	0.0024	CbGpPWpGaD
Nabumetone—Discomfort—Prednisone—chronic obstructive pulmonary disease	7.06e-05	0.000862	CcSEcCtD
Nabumetone—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	7e-05	0.00237	CbGpPWpGaD
Nabumetone—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	6.95e-05	0.000848	CcSEcCtD
Nabumetone—Oedema—Prednisone—chronic obstructive pulmonary disease	6.85e-05	0.000837	CcSEcCtD
Nabumetone—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	6.85e-05	0.000837	CcSEcCtD
Nabumetone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—chronic obstructive pulmonary disease	6.83e-05	0.00231	CbGpPWpGaD
Nabumetone—PTGS1—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	6.8e-05	0.0023	CbGpPWpGaD
Nabumetone—Shock—Prednisone—chronic obstructive pulmonary disease	6.74e-05	0.000823	CcSEcCtD
Nabumetone—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	6.63e-05	0.000809	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	6.53e-05	0.00221	CbGpPWpGaD
Nabumetone—Anorexia—Prednisone—chronic obstructive pulmonary disease	6.53e-05	0.000798	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—IL1B—chronic obstructive pulmonary disease	6.43e-05	0.00218	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—LEP—chronic obstructive pulmonary disease	6.33e-05	0.00214	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—SERPINE1—chronic obstructive pulmonary disease	6.28e-05	0.00213	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	6.28e-05	0.00213	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—ALB—chronic obstructive pulmonary disease	6.27e-05	0.00212	CbGpPWpGaD
Nabumetone—Dizziness—Prednisolone—chronic obstructive pulmonary disease	6.24e-05	0.000762	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	6.22e-05	0.00211	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TLR4—chronic obstructive pulmonary disease	6.2e-05	0.0021	CbGpPWpGaD
Nabumetone—Insomnia—Prednisone—chronic obstructive pulmonary disease	6.2e-05	0.000757	CcSEcCtD
Nabumetone—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	6.15e-05	0.000751	CcSEcCtD
Nabumetone—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	6.03e-05	0.000737	CcSEcCtD
Nabumetone—CYP1A2—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	5.99e-05	0.00203	CbGpPWpGaD
Nabumetone—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	5.96e-05	0.000727	CcSEcCtD
Nabumetone—Rash—Prednisolone—chronic obstructive pulmonary disease	5.95e-05	0.000726	CcSEcCtD
Nabumetone—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	5.94e-05	0.000725	CcSEcCtD
Nabumetone—Fatigue—Prednisone—chronic obstructive pulmonary disease	5.91e-05	0.000721	CcSEcCtD
Nabumetone—Headache—Prednisolone—chronic obstructive pulmonary disease	5.91e-05	0.000721	CcSEcCtD
Nabumetone—PTGS2—Spinal Cord Injury—NOS2—chronic obstructive pulmonary disease	5.9e-05	0.002	CbGpPWpGaD
Nabumetone—Constipation—Prednisone—chronic obstructive pulmonary disease	5.86e-05	0.000716	CcSEcCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—chronic obstructive pulmonary disease	5.82e-05	0.00197	CbGpPWpGaD
Nabumetone—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	5.75e-05	0.00195	CbGpPWpGaD
Nabumetone—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	5.65e-05	0.00069	CcSEcCtD
Nabumetone—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	5.6e-05	0.000684	CcSEcCtD
Nabumetone—Nausea—Prednisolone—chronic obstructive pulmonary disease	5.6e-05	0.000684	CcSEcCtD
Nabumetone—CYP1A2—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	5.51e-05	0.00186	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—APIP—chronic obstructive pulmonary disease	5.47e-05	0.00185	CbGpPWpGaD
Nabumetone—Urticaria—Prednisone—chronic obstructive pulmonary disease	5.45e-05	0.000665	CcSEcCtD
Nabumetone—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	5.42e-05	0.000662	CcSEcCtD
Nabumetone—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	5.42e-05	0.000662	CcSEcCtD
Nabumetone—PTGS2—Selenium Micronutrient Network—IL1B—chronic obstructive pulmonary disease	5.1e-05	0.00173	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	5.06e-05	0.00171	CbGpPWpGaD
Nabumetone—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	5.05e-05	0.000617	CcSEcCtD
Nabumetone—CYP1A2—Biological oxidations—GCLC—chronic obstructive pulmonary disease	5e-05	0.00169	CbGpPWpGaD
Nabumetone—Asthenia—Prednisone—chronic obstructive pulmonary disease	4.92e-05	0.0006	CcSEcCtD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	4.85e-05	0.00164	CbGpPWpGaD
Nabumetone—Pruritus—Prednisone—chronic obstructive pulmonary disease	4.85e-05	0.000592	CcSEcCtD
Nabumetone—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	4.69e-05	0.000573	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—TNF—chronic obstructive pulmonary disease	4.67e-05	0.00158	CbGpPWpGaD
Nabumetone—Dizziness—Prednisone—chronic obstructive pulmonary disease	4.53e-05	0.000553	CcSEcCtD
Nabumetone—Vomiting—Prednisone—chronic obstructive pulmonary disease	4.36e-05	0.000532	CcSEcCtD
Nabumetone—PTGS2—Metabolism—APIP—chronic obstructive pulmonary disease	4.34e-05	0.00147	CbGpPWpGaD
Nabumetone—Rash—Prednisone—chronic obstructive pulmonary disease	4.32e-05	0.000528	CcSEcCtD
Nabumetone—Dermatitis—Prednisone—chronic obstructive pulmonary disease	4.32e-05	0.000527	CcSEcCtD
Nabumetone—Headache—Prednisone—chronic obstructive pulmonary disease	4.29e-05	0.000524	CcSEcCtD
Nabumetone—PTGS2—Spinal Cord Injury—CXCL8—chronic obstructive pulmonary disease	4.21e-05	0.00142	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	4.11e-05	0.00139	CbGpPWpGaD
Nabumetone—Nausea—Prednisone—chronic obstructive pulmonary disease	4.07e-05	0.000497	CcSEcCtD
Nabumetone—PTGS2—Spinal Cord Injury—IL1B—chronic obstructive pulmonary disease	4.04e-05	0.00137	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	3.9e-05	0.00132	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—MMP9—chronic obstructive pulmonary disease	3.81e-05	0.00129	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	3.77e-05	0.00128	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	3.76e-05	0.00127	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—TNF—chronic obstructive pulmonary disease	3.7e-05	0.00125	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	3.7e-05	0.00125	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	3.7e-05	0.00125	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.62e-05	0.00123	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	3.59e-05	0.00122	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	3.56e-05	0.0012	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GC—chronic obstructive pulmonary disease	3.52e-05	0.00119	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	3.52e-05	0.00119	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	3.52e-05	0.00119	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.51e-05	0.00119	CbGpPWpGaD
Nabumetone—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.46e-05	0.00117	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.28e-05	0.00111	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.22e-05	0.00109	CbGpPWpGaD
Nabumetone—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.18e-05	0.00107	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TGFB1—chronic obstructive pulmonary disease	3.14e-05	0.00106	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	3.1e-05	0.00105	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—EGFR—chronic obstructive pulmonary disease	3.08e-05	0.00104	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.05e-05	0.00103	CbGpPWpGaD
Nabumetone—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.01e-05	0.00102	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	2.99e-05	0.00101	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TNF—chronic obstructive pulmonary disease	2.93e-05	0.000991	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.88e-05	0.000973	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.85e-05	0.000965	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GC—chronic obstructive pulmonary disease	2.8e-05	0.000947	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.61e-05	0.000883	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.6e-05	0.00088	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TP53—chronic obstructive pulmonary disease	2.58e-05	0.000874	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	2.46e-05	0.000831	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—IL6—chronic obstructive pulmonary disease	2.36e-05	0.0008	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	2.32e-05	0.000787	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	2.13e-05	0.000722	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	2.09e-05	0.000708	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.07e-05	0.000701	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	1.99e-05	0.000674	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.93e-05	0.000651	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.9e-05	0.000644	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.77e-05	0.0006	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	1.76e-05	0.000594	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.75e-05	0.000593	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CTGF—chronic obstructive pulmonary disease	1.74e-05	0.000588	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.63e-05	0.000551	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.6e-05	0.000541	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	1.58e-05	0.000536	CbGpPWpGaD
Nabumetone—PTGS2—Disease—HDAC2—chronic obstructive pulmonary disease	1.53e-05	0.000519	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.53e-05	0.000517	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GCLC—chronic obstructive pulmonary disease	1.51e-05	0.000511	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.47e-05	0.000498	CbGpPWpGaD
Nabumetone—PTGS2—Disease—KL—chronic obstructive pulmonary disease	1.43e-05	0.000482	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.41e-05	0.000477	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CTGF—chronic obstructive pulmonary disease	1.38e-05	0.000466	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.33e-05	0.000452	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.32e-05	0.000445	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.27e-05	0.00043	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.23e-05	0.000415	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.17e-05	0.000397	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.16e-05	0.000393	CbGpPWpGaD
Nabumetone—PTGS2—Disease—ERBB3—chronic obstructive pulmonary disease	1.07e-05	0.000362	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.06e-05	0.000358	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.04e-05	0.000353	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.74e-06	0.000329	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	9.23e-06	0.000312	CbGpPWpGaD
Nabumetone—PTGS2—Disease—NOS2—chronic obstructive pulmonary disease	8.91e-06	0.000302	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.65e-06	0.000293	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	8.55e-06	0.000289	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	7.97e-06	0.00027	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—ALB—chronic obstructive pulmonary disease	7.9e-06	0.000267	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	7.8e-06	0.000264	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—NOS3—chronic obstructive pulmonary disease	7.56e-06	0.000256	CbGpPWpGaD
Nabumetone—PTGS2—Disease—SERPINE1—chronic obstructive pulmonary disease	7.51e-06	0.000254	CbGpPWpGaD
Nabumetone—PTGS2—Disease—NOS3—chronic obstructive pulmonary disease	7.17e-06	0.000242	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ALB—chronic obstructive pulmonary disease	6.27e-06	0.000212	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—NOS3—chronic obstructive pulmonary disease	6e-06	0.000203	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	6e-06	0.000203	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.91e-06	0.0002	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.51e-06	0.000186	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.22e-06	0.000177	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TGFB1—chronic obstructive pulmonary disease	4.74e-06	0.00016	CbGpPWpGaD
Nabumetone—PTGS2—Disease—EGFR—chronic obstructive pulmonary disease	4.65e-06	0.000157	CbGpPWpGaD
Nabumetone—PTGS2—Disease—IL6—chronic obstructive pulmonary disease	3.57e-06	0.000121	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	3.55e-06	0.00012	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	3.4e-06	0.000115	CbGpPWpGaD
